Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pediatrix Medical Group, Inc. (MD:NYSE), powered by AI.
Pediatrix Medical Group, Inc. is currently trading at $24.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Pediatrix Medical Group, Inc. on Alpha Lenz.
Pediatrix Medical Group, Inc.'s P/E ratio is 12.3.
“Pediatrix Medical Group, Inc. trades at a P/E of 12.3 (undervalued) with strong ROE of 20.3%.”
Ask for details →Pediatrix Medical Group, Inc. operates as a leading provider of physician services within the broader healthcare sector, focusing specifically on neonatal, maternal-fetal, pediatric cardiology, and other related areas. The primary purpose of Pediatrix Medical Group is to ensure specialized and high-quality healthcare for women and children, prioritizing the critical care aspects that are often underserved. Notable for their comprehensive service offerings, Pediatrix plays an essential role in hospital-based management, offering an array of services including clinical staffing, administrative support, and healthcare management solutions. The company's impact on the healthcare industry is significant, as it supports both hospitals and clinics across the United States in delivering superior patient care. As a specialized provider, Pediatrix Medical Group holds a crucial position in addressing the healthcare needs of vulnerable populations, contributing to improved outcomes in neonatal and pediatric care sectors. This strengthens their market significance as they help meet the growing demand for specialized medical services in a dynamic healthcare environment.
“Pediatrix Medical Group, Inc. trades at a P/E of 12.3 (undervalued) with strong ROE of 20.3%.”
Ask for details →Pediatrix Medical Group, Inc. (ticker: MD) is a company listed on NYSE in the Healthcare sector (Medical Care Facilities). It has approximately 4,120 employees. Market cap is $2.0B.
The current price is $24.15 with a P/E ratio of 12.28x and P/B of 2.35x.
ROE is 20.28% and operating margin is 12.07%. Annual revenue is $1.9B.